A major breakthrough in the treatment of amyotrophic lateral sclerosis, known as ALS, can potentially help stop the disease in its tracks in as much as half of the cases in the U.S., a Northeastern University scientist says. Jeffrey Agar, associate professor of chemistry and pharmaceutical sciences at Northeastern, has spent the last 12 years studying the mechanism of ALS and researching ways to prevent its progression. Continue reading →

Aaron Lazar is opening up about his diagnosis with amyotrophic lateral sclerosis (ALS), and revealing why he's not focused on trying to fight the disease for which there is no cure, but instead move through life with courage and hope. The stage veteran known for two decades of roles on Broadway and on tour in musicals like The Light in the Piazza, Dear Evan Hansen, Les Misrables, A Little Night Music and The Last Ship went public in January with the news that he had the progressive neurogenerative disorder, after being diagnosed two years ago. During a candid interview on The Broadway Show with Tamsen Fadal, the 47-year-old actor and singer explained he's since been on a healing journey" focused on taking care of his mind, body and spirit. Continue reading →

image: The image above describes the changes in the mean scores for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) for ALS patients treated with CL2020. Continue reading →

On the heels of promising HEALEY-ALS Phase 2 trial data, Prilenia Therapeutics plans to launch a pivotal Phase 3 study of pridopidine, its candidate amyotrophic lateral sclerosis (ALS) treatment, in the second half of this year. Relative to a placebo, pridopidine was associated with slower disease progression, a better life quality, and a potential to prolong survival in patients in early disease stages. These recently diagnosed ALS patients with rapidly progressing symptoms saw particular benefit in terms of respiratory health and speech, although better speech was evident across all treated patients Continue reading →